

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows.

Please cancel claims 15-18, 24-19, 32 and 33 without prejudice or disclaimer as drawn to a non-elected invention. Please cancel claims 30 and 31 and replace them with new claims 35 and 36.

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-13 (Cancelled)

14. (Currently Amended): ~~The use of a compound that is effective as selective opiate receptor modulator for the manufacture of a pharmaceutical for the diagnosis,~~ A method of prophylaxis and/or the treatment of neuropathy, the clinical pictures and symptoms associated therewith, and related disorders comprising administering an effective dose of N-methyl-N-[(1 S)-1-phenyl-2-((3 S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide, and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof in an enteral or parenteral formulation to a subject in need thereof.

Claims 15-19 (Cancelled)

20. (Currently Amended): ~~The use according to method of claim 14, characterized wherein that the compound that is effective as selective opiate receptor modulator peripherally selective kappa-opiate agonist is N-methyl-N-[(1 S)-1-phenyl-2-((3 S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride, and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof in all ratios.~~

21. (Currently Amended): ~~The use according to method of claim 14, characterized wherein that the related disorders are selected from the group consisting of post-herpetic neuralgia, vulvodinia, lupus erythematosus and chemotherapy induced neuropathy.~~

22. (Currently Amended): ~~The use according to method of claim 20 19, characterized wherein that~~ the related disorders are selected from the group consisting of post-herpetic neuralgia, vulvodynia, lupus erythematosus and chemotherapy induced neuropathy.

23. (Currently Amended): ~~The use according to A method of treating diabetic neuropathy, comprising administering an effective dose of claim 14, characterized in that the compound that is effective as selective opiate receptor modulator is N-methyl-N-[(1 S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof to a subject in need thereof, hydrochloride, and that the disorders are selected from the prophylaxis and the treatment of neuropathy.~~

Claims 24-33 (Cancelled)

34. (New): The method of claim 23, wherein N-methyl-N-[(1 S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride is administered.

35. (New): The method of claim 23, wherein the diabetic neuropathy is painful diabetic neuropathy.

36. (New): The method of claim 34, wherein the diabetic neuropathy is painful diabetic neuropathy.

37. (New): A method of treating a neuropathy related disorder, wherein the neuropathy related disorder is post-herpetic neuralgia, vulvodynia, lupus erythematosus or chemotherapy induced neuropathy, comprising administering a selective opiate receptor modulator to a subject in need thereof.

38. (New): The method of claim 37, wherein the selective opiate receptor modulator is N-methyl-N-[(1 S)-1-phenyl-2-((3 S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide,

and/or a pharmaceutically acceptable derivative, solvate, salt or stereoisomer thereof, including mixtures thereof.

39. (new): The method of claim 38, wherein the selective opiate receptor modulator is N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide hydrochloride.